

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,
 Serial No.: 09/830,836 Examiner: B. Robinson
 Filing Date: 1 May 2001 Art Unit: 1625
 For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

Assistant Commissioner of Patents
 Washington D.C. 20231

#17
 5/17/03

LETTER TO THE EXAMINER

Sir:

Applicants hereby wish to notify the Examiner of the following co-pending applications:

10/212,513 filed 8/5/02
 10/212,514 filed 8/5/02
 10/258,679 filed 10/25/02
 10/168,002 filed 6/14/02 (allowed)
 10/001,600 filed 10/31/02

RECEIVED

MAY 05 2003

TECH CENTER 1600/2900

and the following patent:

US Patent No. 6,451,794 granted 9/17/02 and 6,498,166 granted 12/24/02

The foregoing applications and patents have different inventive entities from the present application but are all commonly assigned.

Respectfully submitted,


 Lorie Ann Morgan
 Attorney for Applicants
 Registration No. 38,181

Date: 15 April, 2003
 GlaxoSmithKline
 Five Moore Drive, PO Box 13398
 Research Triangle Park
 North Carolina 27709
 (919) 483-8222/fax: (919) 483-7988

FIRST CLASS MAIL

gsk

GlaxoSmithKline

Corporate Intellectual Prop.

MAI-B.475.4D

GlaxoSmithKline
Five Moore Drive
PO Box 13398
Research Triangle Park NC 27709-3398

Sender: _____

Extension: _____

Cost Center: _____

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

RECEIVED

MAY 05 2003

TECH CENTER 1600/2900



Returned from
post office
4/30/03.
Present 4/30/03

